• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603998.SS
Share

Hunan Fangsheng Pharmaceutical Co., Ltd. Stocks

CN¥ 10.51Last Updated 09.10.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

CN¥ 678.51M

CN¥ 10.51
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating within China, Hunan Fangsheng Pharmaceutical Co., Ltd. is engaged in the complete spectrum of pharmaceutical activities, from research and development to manufacturing and sales. Its diverse product line encompasses tablets, capsules, and granules, addressing a wide array of therapeutic areas such as cardiovascular, cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infective conditions. The company was established in 2002 and is headquartered in Changsha, China.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBITDA, underv

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 603998.SS is 15.8 and suggests 48.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.10.2026 09:19

Twelve people were killed in an attack on the Riyadh airport

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

10.10.2026 04:58

Palantir shares hit a new high: Barclays followed Goldman in recommending a buy

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026